Pharmacodynamics of WX-0593 combined with bevacizumab biosimilar on human lung cancer xenograft mouse models

被引：0
|
作者：
Zheng, Shansong [1 ]
Zheng, Qingmei [1 ]
Dong, Xin [1 ]
Wang, Xinmei [1 ]
Chen, Dongmei [1 ]
Duan, Huicheng [1 ]
Ma, Cuicui [1 ]
Zhang, Chenwei [1 ]
机构：
[1] Qilu Pharmaceut Co Ltd, Jinan, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5458
引用
收藏
页数：1
相关论文
共 50 条
  • [1] WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations
    Zheng, Qingmei
    Chen, Dongmei
    Wang, Xinmei
    Yang, Yingying
    Zhao, Shuyong
    Dong, Xin
    Ma, Cuicui
    Zhang, Xin
    Duan, Huicheng
    Sun, Yan
    Zheng, Shansong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (12)
  • [2] Iruplinalkib (WX-0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
    Yang, Yingying
    Zheng, Qingmei
    Wang, Xinmei
    Zhao, Shuyong
    Huang, Wenshu
    Jia, Linchao
    Ma, Cuicui
    Liu, Shicong
    Zhang, Yongpeng
    Xin, Qianqian
    Sun, Yan
    Zheng, Shansong
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 254 - 266
  • [3] Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer
    Shi, Y-K.
    Fang, J.
    Zhang, S.
    Liu, Y.
    Wang, L.
    Si, M.
    Ge, M.
    Geng, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Synergistic effects of WX-0593 in combination with panitumumab on osimertinib-resistant EGFR-mutantnon-small cell lung cancer in vitro and in vivo
    Zheng, Shansong
    Zheng, Qingmei
    Chen, Dongmei
    Wang, Xinmei
    Dong, Xin
    Zhang, Xin
    Ma, Cuicui
    Duan, Huicheng
    Zhang, Chenwei
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Efficacy and safety of iruplinalkib (WX-0593) on non-small cell lung cancer with SPECC1L-ALK fusion: A case report
    Zhang, Quan
    Lv, Jialin
    Li, Xi
    Zhang, Hui
    Zhu, Chenlin
    Wang, Meng
    Si, Meimei
    Hu, Ying
    Zhang, Shucai
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2024, 27 (02)
  • [6] A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK plus Non-small Cell Lung Cancer (NSCLC)
    Shi, Y.
    Chen, J.
    Yang, R.
    Wu, H.
    Wang, Z.
    Yang, W.
    Cui, J.
    Zhang, Y.
    Liu, C.
    Cheng, Y.
    Liu, Y.
    Shan, J.
    Wang, D.
    Yang, L.
    Hu, C.
    Zhao, J.
    Cao, R.
    Tan, B.
    Xu, K.
    Si, M.
    Li, H.
    Mao, R.
    Li, L.
    Kang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S50
  • [7] Mouse xenograft models vs GEM models for human cancer therapeutics
    Richmond, Ann
    Su, Yingjun
    DISEASE MODELS & MECHANISMS, 2008, 1 (2-3) : 78 - 82
  • [8] Mouse models for human lung cancer
    Meuwissen, R
    Berns, A
    GENES & DEVELOPMENT, 2005, 19 (06) : 643 - 664
  • [9] Construction of orthotopic xenograft mouse models for human pancreatic cancer
    Dai, Lei
    Lu, Caide
    Yu, Xi
    Dai, Long-Jun
    Zhou, Jeff X.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (03) : 1033 - 1038
  • [10] Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models
    Ishikura, Nobuyuki
    Yanagisawa, Mieko
    Noguchi-Sasaki, Mariko
    Iwai, Toshiki
    Yorozu, Keigo
    Kurasawa, Mitsue
    Sugimoto, Masamichi
    Yamamoto, Kaname
    ANTICANCER RESEARCH, 2017, 37 (02) : 623 - 629
12345